Adverum Biotechnologies, Inc.
Clinical trials sponsored by Adverum Biotechnologies, Inc., explained in plain language.
A clinical-stage gene therapy company focused on ocular diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy shot could end monthly eye injections for wet AMD Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
Gene therapy shot aims to tame wet AMD in both eyes
Disease control Recruiting nowThis study tests a gene therapy called Ixo-vec in the second eye of people with wet age-related macular degeneration (AMD) in both eyes. Fifteen adults aged 50 and older will receive a single injection in the second eye and be followed for about 5 years. The goal is to see if the…
Phase 2 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
One-Shot gene therapy could replace frequent eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of Ixo-vec gene therapy against standard aflibercept injections in 284 people with wet AMD. The goal is to see if Ixo-vec can maintain or improve vision while reducing the need for repeated eye injections. Participants must be at least …
Phase 3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC